Royalty Pharma
RPRX
68.45
+0.73
+1.08%
Royalty Pharma
US · RPRX
#759 by market cap
Listed 2020
68.45
+0.73
+1.08%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 4 in the most recent period (2026/Q4).
- Total institutional ownership fell 0.5 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 87.61% -0.46pp
- Institutions
- 902 -4
- As of
- 2026/Q4 vs. prior period
Holder types
Mutual Fund74.51%
Individual/Insider6.11%
Hedge Fund4.73%
Public Company2.55%
Private Company2.03%
Government Pension Fund1.53%
Sovereign Wealth Fund1.28%
Family Office/Trust0.27%
Endowment Fund0.23%
Insurance Company0.21%
Other6.76%
Top holders as of 2026-09-30
Capital Research
10.21% · 45.48M sh
Morgan Stanley Investment Management Inc.
8.03% · 35.74M sh
BlackRock
6.54% · 29.12M sh
Mario Giuliani
4.80% · 21.37M sh
T. Rowe Price Group, Inc.
3.30% · 14.71M sh
FMR
3.20% · 14.26M sh
State Street Global Advisors
2.91% · 12.95M sh
Swedbank Robur Fonder AB
2.30% · 10.26M sh
Baillie Gifford
2.06% · 9.15M sh
Geode Capital Management, LLC
1.92% · 8.55M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 25 buys · 25 sells
| Name | Role | Stake |
|---|---|---|
| Mario Giuliani | Former Director | 4.80% |
| Pablo Legorreta | Founder, Chairman of the Board & CEO | 1.11% |
| Christopher Hite | Chairman of Partnering & Investments | 0.05% |
| Gregory Norden | Independent Director | 0.04% |
| Marshall Urist | Head of Research & Investments | 0.03% |
| Bonnie Bassler | Independent Director | 0.02% |
| Errol De Souza | Former Independent Director | 0.01% |
| Ted Love | Lead Independent Director | 0.01% |
| Catherine Engelbert | Independent Director | 0.01% |
| David Hodgson | Independent Director | 0.01% |
| Terrance Coyne | Chief Financial Officer | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-05 | Marshall Urist | Head of Research & Investments | Derivative Exercise and Retained | +150,000 | -- |
| 2026-11-05 | Terrance Coyne | Chief Financial Officer | Other Acquisition | +7,122 | -- |
| 2026-11-05 | Terrance Coyne | Chief Financial Officer | Derivative Exercise and Retained | +250,000 | -- |
| 2026-11-03 | Christopher Hite | Chairman of Partnering & Investments | Other Acquisition | +7,122 | -- |
| 2026-11-03 | Marshall Urist | Head of Research & Investments | Other Acquisition | +5,341 | -- |
| 2026-11-03 | Pablo Legorreta | Founder, Chairman of the Board & CEO | Other Acquisition | +42,209 | -- |
| 2026-10-04 | Marshall Urist | Head of Research & Investments | Automatic Disposition | -4,126 | $57.10 |
| 2026-09-29 | Bonnie Bassler | Independent Director | Other Acquisition | +642 | $58.41 |
| 2026-09-27 | Marshall Urist | Head of Research & Investments | Automatic Disposition | -4,126 | $57.88 |
| 2026-09-21 | Christopher Hite | Chairman of Partnering & Investments | Automatic Disposition | -100,000 | $58.51–58.93 |
| 2026-08-18 | Christopher Hite | Chairman of Partnering & Investments | Other Disposition | -16,800 | -- |
| 2026-08-17 | Christopher Hite | Chairman of Partnering & Investments | Automatic Disposition | -100,000 | $59.97 |
| 2026-08-12 | Terrance Coyne | Chief Financial Officer | Automatic Disposition | -11,002 | $58.59–59.14 |
| 2026-08-06 | Marshall Urist | Head of Research & Investments | Other Derivative Disposition | -3,000 | -- |
| 2026-08-06 | Terrance Coyne | Chief Financial Officer | Other Disposition | -18,500 | -- |
| 2026-08-06 | Pablo Legorreta | Founder, Chairman of the Board & CEO | Other Derivative Disposition | -30,000 | -- |
| 2026-08-04 | Christopher Hite | Chairman of Partnering & Investments | Other Acquisition | +11,002 | -- |
| 2026-08-04 | Marshall Urist | Head of Research & Investments | Other Acquisition | +8,252 | -- |
| 2026-08-04 | Terrance Coyne | Chief Financial Officer | Other Acquisition | +11,002 | -- |
| 2026-08-04 | Pablo Legorreta | Founder, Chairman of the Board & CEO | Other Acquisition | +65,216 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:28 · For reference only, not investment advice and not tailored to your situation.
Royalty Pharma discussion 0 comments